IMR Press / FBL / Volume 13 / Issue 16 / DOI: 10.2741/3139

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
T cell responses during allergen-specific immunotherapy of Type I allergy
Show Less
1 Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria

*Author to whom correspondence should be addressed.

 

Front. Biosci. (Landmark Ed) 2008, 13(16), 6079–6085; https://doi.org/10.2741/3139
Published: 1 May 2008
Abstract

Although allergen-specific immunotherapy (SIT) has been performed in humans for already a century, the immune mechanisms underlying this treatment are still not entirely solved. Allergen-specific CD4+ T lymphocytes are considered as pivotal for the induction and maintenance of allergic disorders. Consequently, their role for allergy treatment has been - and still is – of great interest. Whereas two decades ago immune deviation, i.e. the switch from the allergic Th2 response to a Th1-like response, was described as the most important alteration induced by SIT, more recently the induction of allergen-specific regulatory T cells producing IL-10 has been considered as a main event causing peripheral T cell tolerance. In view of very recent data indicating that both mechanisms may occur consecutively during allergy treatment this review summarizes the current understanding of the immunological mechanisms involved in allergy vaccination.

Share
Back to top